Equities Analysts Offer Predictions for TARA Q1 Earnings

Protara Therapeutics, Inc. (NASDAQ:TARA) – Analysts at HC Wainwright lowered their Q1 2026 EPS estimates for shares of Protara Therapeutics in a report released on Wednesday, March 11th. HC Wainwright analyst A. Maldonado now expects that the company will earn ($0.39) per share for the quarter, down from their previous estimate of ($0.33). HC Wainwright currently has a “Buy” rating and a $23.00 target price on the stock. The consensus estimate for Protara Therapeutics’ current full-year earnings is ($3.32) per share. HC Wainwright also issued estimates for Protara Therapeutics’ Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.41) EPS, Q4 2026 earnings at ($0.42) EPS, FY2026 earnings at ($1.61) EPS, FY2027 earnings at ($1.94) EPS, FY2028 earnings at ($1.14) EPS and FY2029 earnings at ($0.44) EPS.

A number of other brokerages have also recently commented on TARA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Protara Therapeutics in a report on Thursday, January 22nd. TD Cowen restated a “buy” rating on shares of Protara Therapeutics in a report on Tuesday. JPMorgan Chase & Co. started coverage on Protara Therapeutics in a research report on Wednesday, March 4th. They issued an “overweight” rating and a $27.00 price target for the company. Finally, Piper Sandler initiated coverage on shares of Protara Therapeutics in a research note on Wednesday, January 7th. They set an “overweight” rating and a $24.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $21.40.

Protara Therapeutics Price Performance

Shares of TARA stock opened at $5.32 on Friday. Protara Therapeutics has a 1 year low of $2.77 and a 1 year high of $7.82. The stock’s 50 day simple moving average is $6.10 and its two-hundred day simple moving average is $5.35. The company has a market cap of $274.67 million, a PE ratio of -4.03 and a beta of 1.40.

Protara Therapeutics (NASDAQ:TARA) last announced its quarterly earnings results on Tuesday, March 10th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03).

Hedge Funds Weigh In On Protara Therapeutics

Large investors have recently bought and sold shares of the business. Virtu Financial LLC bought a new position in Protara Therapeutics in the 4th quarter valued at $368,000. ADAR1 Capital Management LLC grew its holdings in shares of Protara Therapeutics by 3,127.4% in the fourth quarter. ADAR1 Capital Management LLC now owns 1,136,799 shares of the company’s stock worth $6,059,000 after purchasing an additional 1,101,576 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Protara Therapeutics in the fourth quarter worth about $615,000. Sphera Funds Management LTD. purchased a new position in Protara Therapeutics in the 4th quarter worth about $3,464,000. Finally, Quadrature Capital Ltd lifted its holdings in Protara Therapeutics by 39.4% during the 4th quarter. Quadrature Capital Ltd now owns 24,184 shares of the company’s stock valued at $129,000 after buying an additional 6,838 shares in the last quarter. Hedge funds and other institutional investors own 38.13% of the company’s stock.

Trending Headlines about Protara Therapeutics

Here are the key news stories impacting Protara Therapeutics this week:

• Positive Sentiment: Lifesci Capital raised multiple 2026 quarterly EPS estimates (Q1→($0.34), Q2→($0.37), Q3→($0.39), Q4→($0.41)) and boosted its FY2026 view to ($1.49) from ($1.73), signaling a modestly improved near‑term outlook. MarketBeat: TARA
• Neutral Sentiment: HC Wainwright kept a “Buy” rating and a $23.00 price target on TARA, which supports upside expectations if clinical/operational milestones are met even as their model was revised. MarketBeat: TARA
• Negative Sentiment: HC Wainwright lowered several near‑term and long‑range EPS estimates — cutting Q1–Q4 2026 forecasts (e.g., Q1 to ($0.39), Q2 to ($0.40), Q3 to ($0.41), Q4 to ($0.42)) and reducing FY2026 to ($1.61) from ($1.37) and FY2027–FY2029/FY2028 expectations as well — indicating a weaker revenue/profit trajectory in their model and adding downside pressure. MarketBeat: TARA

About Protara Therapeutics

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.